Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists
Two-part preclincal and clinical development programme launched to assess potential benefits of…
EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer
These results indicate that EXACT Therapeutics’ Acoustic Cluster Therapy (ACT®) significantly enhances…
Respira Therapeutics Announces Late-breaking Presentation of RT234 Phase 2b PAH Clinical Trial Results at the American Thoracic Society (ATS) 2025 International Conference
May 19, 2025 08:00 ET | Source: Respira Therapeutics, Inc PALO ALTO,…
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Slowing of progression of disease observed via MRI at 24 months Improvements…
Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene WritingPrograms and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting
May 17, 2025 06:00 ET | Source: Tessera Therapeutics Presented new preclinical…
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics…
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
May 10, 2025 10:00 ET | Source: Akero Therapeutics Inc. Analysis of…
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational…
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 08, 2025 07:00 ET | Source: Cullinan Therapeutics, Inc. Company received…
Xilio Therapeutics Announces Inducement Grant UnderNasdaq Listing Rule 5635(c)(4)
May 02, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…